{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:59:23Z","timestamp":1792292363309,"version":"4.4.0"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2011,4,13]],"date-time":"2011-04-13T00:00:00Z","timestamp":1302652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The multitargeted tyrosine-kinase inhibitor sunitinib has emerged as one of the standards of care for good- and intermediate-risk metastatic renal cell carcinoma. Although generally associated with acceptable toxicity, sunitinib exhibits a novel and distinct toxicity profile that requires monitoring and management. Fatigue, diarrhea, anorexia, oral changes, hand-foot syndrome and other skin toxicity, thyroid dysfunction, myelotoxicity, and hypertension seem to be the most common and clinically relevant toxicities of sunitinib. Drug dosing and treatment duration are correlated with response to treatment and survival. Treatment recommendations for hypertension have been published but, currently, no standard guidelines exist for the management of noncardiovascular side effects. To discuss the optimal management of noncardiovascular side effects, an international, interdisciplinary panel of experts gathered in November 2009. Existing literature on incidence, severity, and underlying mechanisms of side effects as well as on potential treatment options were carefully reviewed and discussed. On the basis of these proceedings and the thorough review of the existing literature, recommendations were made for the monitoring, prevention, and treatment of the most common noncardiovascular side effects and are summarized in this review. The proactive assessment and consistent and timely management of sunitinib-related side effects are critical to ensure optimal treatment benefit by allowing appropriate drug dosing and prolonged treatment periods.<\/jats:p>","DOI":"10.1634\/theoncologist.2010-0263","type":"journal-article","created":{"date-parts":[[2011,4,13]],"date-time":"2011-04-13T21:10:02Z","timestamp":1302729002000},"page":"543-553","source":"Crossref","is-referenced-by-count":69,"title":["Sunitinib in Metastatic Renal Cell Carcinoma: Recommendations for Management of Noncardiovascular Toxicities"],"prefix":"10.1093","volume":"16","author":[{"given":"Christian","family":"Kollmannsberger","sequence":"first","affiliation":[{"name":"a British Columbia Cancer Agency Vancouver Cancer Centre, Vancouver, British Columbis, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Bjarnason","sequence":"additional","affiliation":[{"name":"b Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Burnett","sequence":"additional","affiliation":[{"name":"c Vanderbilt University Medical Center, Nashville, Tennessee, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Creel","sequence":"additional","affiliation":[{"name":"d Duke University Medical Center, Durham, North Carolina, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mellar","family":"Davis","sequence":"additional","affiliation":[{"name":"e Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Dawson","sequence":"additional","affiliation":[{"name":"f Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D.C., USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Feldman","sequence":"additional","affiliation":[{"name":"g Memorial Sloan-Kettering Cancer Center, New York, New York, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"George","sequence":"additional","affiliation":[{"name":"h Dana Farber Cancer Institute, Boston, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Hershman","sequence":"additional","affiliation":[{"name":"i David Geffen School of Medicine, Los Angeles, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lechner","sequence":"additional","affiliation":[{"name":"j Pfizer Oncology, New York, New York, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Potter","sequence":"additional","affiliation":[{"name":"h Dana Farber Cancer Institute, Boston, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Raymond","sequence":"additional","affiliation":[{"name":"k Service Inter-Hospitalier de Canc\u00e9rologie Beaujon-Bichat, Clichy, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Treister","sequence":"additional","affiliation":[{"name":"l Brigham and Women's Hospital, Boston, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Wood","sequence":"additional","affiliation":[{"name":"e Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenhong","family":"Wu","sequence":"additional","affiliation":[{"name":"m Stony Brook University Medical Center, Stony Brook, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Bukowski","sequence":"additional","affiliation":[{"name":"e Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,4,13]]},"reference":[{"key":"2021122303331745600_B1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122303331745600_B2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","article-title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122303331745600_B3","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","article-title":"Sunitinib in patients with metastatic renal cell carcinoma","volume":"295","author":"Motzer","year":"2006","journal-title":"JAMA"},{"key":"2021122303331745600_B4","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1200\/JCO.2005.01.186","article-title":"Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma","volume":"23","author":"Rini","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122303331745600_B5","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1200\/JCO.2006.08.5415","article-title":"Targeted therapy for metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122303331745600_B6","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","article-title":"Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis","volume":"66","author":"Houk","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122303331745600_B7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":"Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial","volume":"10","author":"Gore","year":"2009","journal-title":"Lancet Oncol"},{"key":"2021122303331745600_B8","volume-title":"Common Terminology Criteria for Adverse Events v3.0. May 22, 2003","author":"CTEP NCI"},{"key":"2021122303331745600_B9","article-title":"Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors","volume":"22","author":"Rosen","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122303331745600_B10","article-title":"Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST)","volume":"23","author":"Maki","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122303331745600_B11","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.e15115","volume-title":"Schedule modifications and treatment outcomes for sunitinib-related adverse events","author":"Atkinson","year":"2010"},{"key":"2021122303331745600_B12","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/S0140-6736(07)61874-1","article-title":"Targeted drugs for metastatic renal cell carcinoma","volume":"370","author":"Motzer","year":"2007","journal-title":"Lancet"},{"key":"2021122303331745600_B13","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1200\/JCO.2006.10.5916","article-title":"Phase I\/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma","volume":"25","author":"Motzer","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122303331745600_B14","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jpainsymman.2008.12.003","article-title":"Cancer-related fatigue: central or peripheral?","volume":"38","author":"Yavuzsen","year":"2009","journal-title":"J Pain Symptom Manage"},{"key":"2021122303331745600_B15","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1152\/physrev.2001.81.4.1725","article-title":"Spinal and supraspinal factors in human muscle fatigue","volume":"81","author":"Gandevia","year":"2001","journal-title":"Physiol Rev"},{"key":"2021122303331745600_B16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jnci\/djk008","article-title":"Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"99","author":"Rini","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2021122303331745600_B17","first-page":"CD006704","article-title":"Drug therapy for the management of cancer related fatigue","author":"Minton","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122303331745600_B18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ctrv.2009.11.003","article-title":"Exercise and cancer rehabilitation: a systematic review","volume":"36","author":"Spence","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"2021122303331745600_B19","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.nut.2005.06.003","article-title":"Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy","volume":"22","author":"Gramignano","year":"2006","journal-title":"Nutrition"},{"key":"2021122303331745600_B20","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.2174\/092986710791233689","article-title":"Clinical uses of melatonin: evaluation of human trials","volume":"17","author":"S\u00e1nchez-Barcel\u00f3","year":"2010","journal-title":"Curr Med Chem"},{"key":"2021122303331745600_B21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00520-009-0642-2","article-title":"Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA","volume":"18","author":"Barton","year":"2010","journal-title":"Support Care Cancer"},{"key":"2021122303331745600_B22","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-145-9-200611070-00008","article-title":"Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors","volume":"145","author":"Desai","year":"2006","journal-title":"Ann Intern Med"},{"key":"2021122303331745600_B23","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1056\/NEJMc070327","article-title":"Sunitinib and hypothyroidism","volume":"356","author":"Wolter","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122303331745600_B24","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/thy.2006.0308","article-title":"Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity","volume":"17","author":"Wong","year":"2007","journal-title":"Thyroid"},{"key":"2021122303331745600_B25","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2265.2008.03253.x","article-title":"Thyrotoxicosis during sunitinib treatment for renal cell carcinoma","volume":"69","author":"Grossmann","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2021122303331745600_B26","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1210\/jc.2007-0586","article-title":"A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake","volume":"92","author":"Mannavola","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122303331745600_B27","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/sj.bjc.6604497","article-title":"The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation","volume":"99","author":"Wolter","year":"2008","journal-title":"Br J Cancer"},{"key":"2021122303331745600_B28","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cncr.25422","article-title":"Hypothyroidism in patients with renal cell carcinoma: blessing or curse?","volume":"117","author":"Schmidinger","year":"2011","journal-title":"Cancer"},{"key":"2021122303331745600_B29","article-title":"The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study","author":"Baldazzi","year":"2010","journal-title":"Urol Oncol"},{"key":"2021122303331745600_B30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122303331745600_B31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10238-007-0145-8","article-title":"Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib","volume":"7","author":"Porta","year":"2007","journal-title":"Clin Exp Med"},{"key":"2021122303331745600_B32","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1634\/theoncologist.12-10-1178","article-title":"Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib","volume":"12","author":"Beldner","year":"2007","journal-title":"The Oncologist"},{"key":"2021122303331745600_B33","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/archderm.144.1.123","article-title":"Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis","volume":"144","author":"Suwattee","year":"2008","journal-title":"Arch Dermatol"},{"key":"2021122303331745600_B34","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122303331745600_B35","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1365-2133.2007.08357.x","article-title":"Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy","volume":"158","author":"Yang","year":"2008","journal-title":"Br J Dermatol"},{"key":"2021122303331745600_B36","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/annonc\/mdi204","article-title":"Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?","volume":"16","author":"Jacobi","year":"2005","journal-title":"Ann Oncol"},{"key":"2021122303331745600_B37","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/01.rli.0000124457.99229.bb","article-title":"Validation of a new method for quantifying in vivo murine tumor necrosis by sonography","volume":"39","author":"Rouffiac","year":"2004","journal-title":"Invest Radiol"},{"key":"2021122303331745600_B38","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1096\/fj.03-0271fje","article-title":"Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms","volume":"18","author":"Erber","year":"2004","journal-title":"FASEB J"},{"key":"2021122303331745600_B39","doi-asserted-by":"crossref","first-page":"5786","DOI":"10.1200\/JCO.2006.08.6868","article-title":"Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma","volume":"24","author":"Tsai","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122303331745600_B40","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"key":"2021122303331745600_B41","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/j.1468-3083.2006.02123.x","article-title":"Eccrine squamous syringometaplasia associated with sunitinib therapy","volume":"21","author":"Sheen","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2021122303331745600_B42","article-title":"Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma: update of a multicenter phase II trial","volume":"24","author":"Thompson","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122303331745600_B43","first-page":"71","article-title":"Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors","volume":"32","author":"Alexandrescu","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"2021122303331745600_B44","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1096\/fj.00-0368com","article-title":"SCF\/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit","volume":"15","author":"Botchkareva","year":"2001","journal-title":"FASEB J"},{"key":"2021122303331745600_B45","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/34681","article-title":"MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes","volume":"391","author":"Hemesath","year":"1998","journal-title":"Nature"},{"key":"2021122303331745600_B46","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1345\/aph.1K592","article-title":"Sunitinib adverse event: oral bullous and lichenoid mucositis","volume":"43","author":"Mignogna","year":"2009","journal-title":"Ann Pharmacother"},{"key":"2021122303331745600_B47","first-page":"869","article-title":"Vascular endothelial growth factor in normal human salivary glands and saliva: a possible role in the maintenance of mucosal homeostasis","volume":"78","author":"Taichman","year":"1998","journal-title":"Lab Invest"},{"key":"2021122303331745600_B48","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1002\/cncr.20163","article-title":"Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis","volume":"100","author":"Rubenstein","year":"2004","journal-title":"Cancer"},{"key":"2021122303331745600_B49","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.ijrobp.2005.12.004","article-title":"Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases","volume":"64","author":"Lordick","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122303331745600_B50","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1345\/aph.1C510","article-title":"Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists","volume":"37","author":"Navari","year":"2003","journal-title":"Ann Pharmacother"},{"key":"2021122303331745600_B51","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S1359-6349(09)71451-X","article-title":"An Asian subpopulation analysis of the safety and efficacy of sunitinib in metastatic renal cell carcinoma","volume":"7","author":"Lee","year":"2009","journal-title":"Eur J Cancer Suppl"},{"key":"2021122303331745600_B52","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1177\/42.11.7523489","article-title":"Expression of c-kit and kit ligand proteins in normal human tissues","volume":"42","author":"Lammie","year":"1994","journal-title":"J Histochem Cytochem"},{"key":"2021122303331745600_B53","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1188\/07.CJON.99-113","article-title":"Putting evidence into practice: evidence-based interventions for fatigue during and following cancer and its treatment","volume":"11","author":"Mitchell","year":"2007","journal-title":"Clin J Oncol Nurs"},{"key":"2021122303331745600_B54","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1188\/09.CJON.336-341","article-title":"Putting evidence into practice: evidence-based interventions to prevent, manage, and treat chemotherapy- and radiotherapy-induced diarrhea","volume":"13","author":"Muehlbauer","year":"2009","journal-title":"Clin J Oncol Nurs"},{"key":"2021122303331745600_B55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1188\/09.CJON.95-102","article-title":"Putting evidence into practice: evidence-based interventions to prevent and manage anorexia","volume":"13","author":"Adams","year":"2009","journal-title":"Clin J Oncol Nurs"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2010-0263","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2010-0263","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/5\/543\/41854025\/oncolo_16_5_543.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/5\/543\/41854025\/oncolo_16_5_543.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:38:43Z","timestamp":1640219923000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/16\/5\/543\/6400865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,13]]},"references-count":55,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2011,4,13]]},"published-print":{"date-parts":[[2011,5,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2010-0263","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,5,1]]},"published":{"date-parts":[[2011,4,13]]}}}